PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33905761-9	2021	Pretreatment with SP600125, a JNK inhibitor, could significantly block the promotion effects of FB1 on OTA-induced nephrocytotoxicity and apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Sus scrofa	30-33	
34353852-5	2021	ET-1-induced vasoconstriction was abolished in the absence of extracellular Ca2+ and sensitive to c-Jun N-terminal kinase (JNK) inhibitor SP600125 but unaffected by extracellular signal-regulated kinase (ERK) inhibitor PD98059, p38 kinase inhibitor SB203580, or a broad-spectrum PKC inhibitor Go 6983.	pyrazolanthrone	138-146	mitogen-activated protein kinase 8	Sus scrofa	98-121	
34353852-5	2021	ET-1-induced vasoconstriction was abolished in the absence of extracellular Ca2+ and sensitive to c-Jun N-terminal kinase (JNK) inhibitor SP600125 but unaffected by extracellular signal-regulated kinase (ERK) inhibitor PD98059, p38 kinase inhibitor SB203580, or a broad-spectrum PKC inhibitor Go 6983.	pyrazolanthrone	138-146	mitogen-activated protein kinase 8	Sus scrofa	123-126	
28703856-7	2018	Expression of ET-1 was increased by stroke and potentiated by tPA but returned to sham levels by tPA-A296-299 and the JNK antagonist SP600125.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Sus scrofa	118-121	
33546770-2	2021	Treatment with SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can suppress the JNK signaling pathway to alleviate donor liver ischemia-reperfusion injury (IRI).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Sus scrofa	41-64	
33546770-2	2021	Treatment with SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can suppress the JNK signaling pathway to alleviate donor liver ischemia-reperfusion injury (IRI).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Sus scrofa	66-69	
33546770-2	2021	Treatment with SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can suppress the JNK signaling pathway to alleviate donor liver ischemia-reperfusion injury (IRI).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Sus scrofa	89-92	
29476447-8	2019	wt-tPA co-administered with the JNK inhibitor SP 600125 and the ET-1 antagonist BQ 123 blocked stroke-induced elevation of IL-6.	pyrazolanthrone	46-55	mitogen-activated protein kinase 8	Sus scrofa	32-35	
26908192-7	2016	Moreover, arecoline (0.25 mM) activated JNK while SP600125 (a JNK inhibitor) attenuated arecoline-induced TGF-beta gene transcriptional activity.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Sus scrofa	62-65	
27556216-8	2016	Treatment of either acute or chronic hyperglycemic vessels with JNK inhibitor SP600125 or JNK-interacting protein-1 (JIP1) inhibitor BI-78D3, but not p38 inhibitor SB203580, preserved bradykinin-induced dilation in an L-NAME-sensitive manner.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Sus scrofa	64-67	
16352304-5	2006	In contrast, administration of SP 600125 (10(-6) and 10(-5) M) (JNK MAPK inhibitor) only attenuated brain injury induced U 46619 potentiation and such responses were significantly different than that in the presence of either U 0126 or SB 203580 after FPI.	pyrazolanthrone	31-40	mitogen-activated protein kinase 8	Sus scrofa	64-67	
16827853-6	2006	However, the inhibition of JNK pathway, with the specific SP600125 inhibitor, in the presence of PEG 35,000 Da did not affect cell survival.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Sus scrofa	27-30	
23577046-7	2012	In contrast, both pre- or post-injury thrombosis injection of RBC-tPA and JNK antagonist SP 600125 prevented impairment of Katp- and Kca-induced vasodilation.	pyrazolanthrone	89-98	mitogen-activated protein kinase 8	Sus scrofa	74-77	
21756552-8	2011	RESULTS: CSF JNK MAPK was increased by FPI, increased further by tPA, but blocked by JNK antagonists SP600125 and D-JNKI1.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Sus scrofa	13-16	
21756552-8	2011	RESULTS: CSF JNK MAPK was increased by FPI, increased further by tPA, but blocked by JNK antagonists SP600125 and D-JNKI1.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Sus scrofa	85-88	
20222869-5	2010	In an attempt to elucidate the signalling pathway involved, PDTC (pyrrolidinedithiocarbamate), SP600125 and FK009 respectively inhibitors of NF-kappaB, c-JNK and caspases, were added to the cells in the presence and absence of TNF, and changes in the activities of JNK and PDTC were determined.	pyrazolanthrone	95-103	mitogen-activated protein kinase 8	Sus scrofa	154-157	
16099438-3	2005	FPI blunted PGE2 pial artery dilation, but U 0126 and SP 600125 (10(-6) M) (ERK and JNK MAPK inhibitors, respectively) partially prevented such impairment (7 +/- 1, 12 +/- 1, and 17 +/- 1 vs. 2 +/- 1, 3 +/- 1, and 5 +/- 1 vs. 4 +/- 1, 7 +/- 1, and 12 +/- 1% for 1, 10, and 100 ng/ml PGE2 in control, FPI, and FPI + U 0126 pretreated animals, respectively).	pyrazolanthrone	54-63	mitogen-activated protein kinase 8	Sus scrofa	84-87	
15944157-6	2005	In contrast, inhibition of JNK with SP600125 maintained cell adhesion as well as protection against apoptosis.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Sus scrofa	27-30